Background
American Head and Neck Society (AHNS) consensus statement and evidence review on the role of external beam RT (EBRT) in differentiated thyroid cancer (DTC: papillary, follicular), addressing patient selection, dosing, and integration with other therapies.
Interventions and follow up
Document type: AHNS consensus statement on EBRT indications in DTC
Primary endpoint: Consensus recommendations for EBRT use in DTC
mFollow up: Not applicable
Primary endpoint: Consensus recommendations for EBRT use in DTC
mFollow up: Not applicable
Results
Routine use: EBRT not routinely recommended for DTC
Indications: Gross extrathyroidal extension with positive/close margins (esp. age >45 with aggressive histology); unresectable locoregional recurrence not amenable to RAI; palliation of symptomatic disease
Dose: 60-66 Gy with modern techniques (IMRT preferred for normal-tissue sparing)
Caveat: EBRT should not replace surgery as primary definitive treatment
Indications: Gross extrathyroidal extension with positive/close margins (esp. age >45 with aggressive histology); unresectable locoregional recurrence not amenable to RAI; palliation of symptomatic disease
Dose: 60-66 Gy with modern techniques (IMRT preferred for normal-tissue sparing)
Caveat: EBRT should not replace surgery as primary definitive treatment
Adverse events
Neck EBRT toxicity: Esophagitis, xerostomia (if salivary glands in field), fibrosis
High-dose risk: Laryngeal/tracheal injury
High-dose risk: Laryngeal/tracheal injury
Conclusions
EBRT has a limited but defined role in DTC — adjuvant therapy for unresectable disease, positive/close margins after surgery in high-risk patients, and palliation. Routine adjuvant EBRT after complete resection is not supported.
Key Limitations
Consensus statement, not a trial; underlying evidence largely retrospective and low-quality; indications rely on expert opinion; no randomized data defining EBRT benefit in DTC.
Clinical Context
Aligns with 2015 ATA guidelines (Haugen 2016) in restricting EBRT to select high-risk/unresectable DTC. Provides radiation-oncology-specific dosing (60-66 Gy IMRT) and patient-selection guidance complementing the broader ATA framework.